Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sekine, M.
Right arrow Articles by Tanaka, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sekine, M.
Right arrow Articles by Tanaka, K.
Clinical Cancer Research Vol. 7, 3144-3150, October 2001
© 2001 American Association for Cancer Research


Regular Articles

Mutational Analysis of BRCA1 and BRCA2 and Clinicopathologic Analysis of Ovarian Cancer in 82 Ovarian Cancer Families

Two Common Founder Mutations of BRCA1 in Japanese Population1

Masayuki Sekine, Hiroshi Nagata, Shoji Tsuji, Yasuo Hirai, Seiichiro Fujimoto, Masayuki Hatae, Iwao Kobayashi, Tsuneo Fujii, Ichiro Nagata, Kimio Ushijima, Koshiro Obata, Mitsuaki Suzuki, Mitsuhiro Yoshinaga, Naohiko Umesaki, Shinji Satoh, Takayuki Enomoto, Satoru Motoyama, Kenichi Tanaka2 and The Japanese Familial Ovarian Cancer Study Group,3

Department of Obstetrics and Gynecology [M. S., H. N., K. T.] and Neurology [S. T.], Niigata University, School of Medicine, Niigata 951-8510; Department of Gynecology, Cancer Institute Hospital, Tokyo 170-8455 [Y. H.]; Department of Obstetrics and Gynecology, Hokkaido University, School of Medicine, Hokkaido 060-8638 [S. F.]; Department of Obstetrics and Gynecology, Kagoshima City Hospital, Kagoshima 892-8580 [M. H.]; Department of Obstetrics and Gynecology, Nagoya Daini Red Cross Hospital, Aichi 466-8650 [I. K.]; Department of Obstetrics and Gynecology, National Kure Medical Center, Hiroshima 737-0023 [T. F.]; Department of Obstetrics and Gynecology, National Defense Medical College, Saitama 359-8513 [I. N.]; Department of Obstetrics and Gynecology, Kurume University, School of Medicine, Fukuoka 830-0011 [K. U.]; Department of Obstetrics and Gynecology, Kinki University, School of Medicine, Osaka 589-8511 [K. O.]; Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi 329-0498 [M. S.]; Department of Obstetrics and Gynecology, Kagoshima University, School of Medicine, Kagoshima 890-8520 [M. Y.]; Department of Obstetrics and Gynecology, Osaka City University, School of Medicine, Osaka 545-8585 [N. U.]; Department of Obstetrics and Gynecology, Tohoku University, School of Medicine, Miyagi 980-8575 [S. S.]; Department of Obstetrics and Gynecology, Osaka University, School of Medicine, Osaka 565-0871 [T. E.]; and Department of Obstetrics and Gynecology, Kobe University, School of Medicine, Hyogo 650-0017 [S. M.], Japan

We analyzed genetic alterations in BRCA1 and BRCA2 genes among 82 ovarian cancer families in Japan. The clinical characteristics of BRCA-associated ovarian cancer patients were compared with cases carrying no mutations as well as with population controls. Using a direct sequencing method, 45 of the 82 ovarian cancer families were found to carry BRCA1 or BRCA2 germ-line mutations (40 with BRCA1 and 5 with BRCA2). In 24 independent mutations of BRCA1, 5 recurrent mutations were found and 2 of them, the L63X and Q934X mutations, were detected in seven and eight independent families, respectively. In addition, 16 mutations of BRCA1 and 3 mutations of BRCA2 have never been described previously. In consideration of clinicopathological features, there was a significantly higher proportion of tumors with serous adenocarcinoma and of cases of advanced stages in the BRCA1 or BRCA2 cases than in those of the controls. On the other hand, there were no differences of mean age at diagnosis between patients with BRCA1 or BRCA2 mutation and those of the controls. Our results indicate that the features of BRCA-associated ovarian cancer in Japan appear to be similar to those in Western countries, and the L63X and Q934X mutations of BRCA1 appear to be common founder mutations unique to the Japanese population.




This article has been cited by other articles:


Home page
Cancer Res.Home page
N. Mirkovic, M. A. Marti-Renom, B. L. Weber, A. Sali, and A. N. A. Monteiro
Structure-Based Assessment of Missense Mutations in Human BRCA1: Implications for Breast and Ovarian Cancer Predisposition
Cancer Res., June 1, 2004; 64(11): 3790 - 3797.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.